Neuronostics develops BioEP, a clinically validated digital biomarker platform that analyses standard EEG recordings using eight predefined computational biomarkers and produces a report in under five minutes. The platform is UKCA-marked and ISO-13485 certified and has been validated across 15 NHS sites with over 1,000 recordings. NHS service evaluations are underway at multiple Trusts, including The Royal Wolverhampton NHS Trust and University Hospitals Dorset, and the company has a strategic partnership with Stratus to support scalable US deployment. Neuronostics plans to pursue FDA clearance (with a submission planned for 2026) and to extend the platform to provide brain fingerprints of treatment response in pharmaceutical trials. The company highlights clinical needs such as long diagnostic wait times, high misdiagnosis rates, and the high rate of inconclusive routine EEGs as drivers for its adoption.

Total raised

$8M

Funding rounds

4

Latest round

Grant

Latest activity

Jun 2026